Vagifem® + Non-Vagifem® LDVE, Estradiol
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Postmenopausal Vaginal Atrophy
Conditions
Postmenopausal Vaginal Atrophy
Trial Timeline
Jan 15, 2022 → Jul 31, 2022
NCT ID
NCT05243823About Vagifem® + Non-Vagifem® LDVE, Estradiol
Vagifem® + Non-Vagifem® LDVE, Estradiol is a pre-clinical stage product being developed by Novo Nordisk for Postmenopausal Vaginal Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT05243823. Target conditions include Postmenopausal Vaginal Atrophy.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05243823 | Pre-clinical | Completed |
Competing Products
20 competing products in Postmenopausal Vaginal Atrophy